In this slideshow, we highlight the news you may have missed: Prescribing information for a newly approved treatment for pediatric lupus, new reports on negative pregnancy outcomes in PsA and ankylosing spondylitis, new information on the benefits of daily tofacitinib, and much more.
In this slideshow, we highlight the news you may have missed:Â Prescribing information for a newly approved treatment for pediatric lupus, new reports on negative pregnancy outcomes in PsA and ankylosing spondylitis, new information on the benefits of daily tofacitinib, and much more.
DAILY TOFACITINIB BENEFICIAL IN RHEUMATOID ARTHRITIS: Tofacitinib 5 or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows. A second study we featured this week shows that tofacitinib is associated with a low risk of venous thromboembolism. (©Unguryanu, AdobeStock.com)
FDA RHEUMATOLOGY DRUG APPROVALS: From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics. (©iQoncept,AdobeStock)
EXERCISE LOWERS RISK OF RHEUMATOIID ARTHRITIS: In a study published in a recent Arthritis & Rheumatology issue, investigators discovered physical activity and a lower body mass index (BMI) can significantly decrease the likelihood a a woman will develop this chronic condition.(©SydaProductions,Shutterstock)
TREATMENT GUIDELINES FOR GLUCOCORTICOID USE TO PREVENT BONE LOSS: Glucocorticoids are highly effective in treating inflammatory conditions. However, these medications also pose a significant risk for bone loss and fracture. In this slideshow, we cover the treatment guidelines. (©AdobeStock_Crevis)
ADVERSE PREGNANCY OUTCOMES RISE WITH ACTIVE PSA/AS DISEASE AND CORTICOSTEROID USE: Active psoriatic arthritis and ankylosing spondylitis can lead to adverse pregnancy outcomes, which grows with corticosteroid use, a study shows. (©HaveANiceDayPhotoShutterstock.com)
CONVENTIONAL TREATMENT SHOWS SOME EFFICACY IN JUVENILE IDIOPATHIC ARTHRITIS: Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows. (©Sebastian, AdobeStock.com)
WHICH BIOLOGICS DO PATIENTS LIKE BEST? Which biologics do patients like best? Does methotrexate cause intestinal lung disease? A combination treatment that reduces bad cholesterol. These are among the studies we highlight in this week's weekend slideshow. (©AfricaStudio, Shutterstock)
REMISSION IN AXIAL SPONDYLOARTHRITIS UNLIKELY WITHOUT BIOLOGICS: Remission is unlikely in non-radiographic axial spondyloarthritis without biologic therapy. Adding certolizumab to background therapy can lead to significant improvements in disease activity compared to placebo, researchers find. (©Choo, AdobeStock.com)
BIOMARKERS FOR DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: In a recent edition of Frontiers in Immunology, Dr. Walter Maksymowych, University of Alberta, reviews the use of biomarkers for diagnosis and prognosis in axial spondyloarthritis. Learn more in this summary. (©Angellodeco, AdobeStock.com)
MANAGING RHEUMATIC MEDICATIONS AFTER HIP OR KNEE SURGERY: To help clinicians manage antirheumatic drug therapy, the ACR and the American Association of Hip and Knee Surgeons developed evidence-based guidelines for the perioperative management of antirheumatic medication for patients with rheumatic diseases undergoing knee or hip surgery. In this slideshow, we outline those recommendations. (©Piotr_Pabijan,Shutterstock.com; ©Lightspring,ShutterStock.com)